Opioid Dependence

The following studies have contributed to our Opioid Dependence datasets.

Study 03 – Molecular Genetics of Heroin Dependence in China

Investigators:  Ming Tsuang, Steve Faraone Status:  Available at NIDA and dbGaP SPECIFIC AIMS: Although the available data strongly suggest that a substantial component of the etiology of drug dependence is mediated by gene expression in the central nervous system (Tsuang et al., 1996; Tsuang et al., 1998), a detailed understanding of the mechanisms involved has remained elusive.  Genetic studies have...

Read more ...

Study 05 – Addictions, Genotypes, Polymorphisms, and Function

Investigator:  Mary Jeanne Kreek Status:  Available at NIDA and dbGaP dbGaP Accession ID: phs001109.v1.p1 Abstract:  Information on this diagnostic instrument is provided as documentation for the NIDA consortium, and is to be used for informational purposes only.  Further information about the SCID can be found at the SCID website.  Drug addiction continues to be a major medical and social problem....

Read more ...

Study 08 – Mu Opioid Receptor Gene in Heroin Addicts

Investigator:  Lei Yu Status:  Available at NIDA Abstract:  Addiction to heroin is a major social problem, affecting over a million people in the United States. In the body and brain, heroin is hydrolyzed to morphine, which acts at the mu opioid receptor and results in a euphoric effect, thus conferring the reinforcing properties of the drug and contributing to addiction....

Read more ...

Study 14 – Genome-Wide Analysis for Addiction Susceptibility Genes

Investigator:  Herbert Lachman Status:  Available at NIDA and dbGaP Abstract (adapted from applicant's abstract): This is an R01 application for funding to identify chromosomal markers linked to drug dependence. The use of illicit, highly addictive drugs is a major public health and legal problem in the United States and around the world. There is an urgent need for new pharmacological...

Read more ...

Study 17 – Opioid Dependence

Investigator:  Wade Berrettini Status:  Available at NIDA and dbGaP Abstract:  This application proposes a genetic study of the mu opioid receptor gene (OPRM1) as a predictor of risk for opioid dependence (OD).   Pharmacologic, genetic and behavioral studies suggest that risk for OD may be mediated in part by sequence variation in OPRM1 gene.  The study will be conducted in...

Read more ...

Study 18 – Opioid Dependence: Candidate Genes and G x E Effects

Investigator:  Elliot Nelson Status:  Available at NIDA Abstract:  This project seeks to achieve a better understanding of the interaction between genetic and environmental factors have been demonstrated to be associated with risk for opioid dependence. The design incorporates childhood trauma history as a risk modifying variable in a case-control genetic association study of opioid dependence. Cases (N=1500) will be ascertained...

Read more ...

Study 24 – START Pharmacogenetics: Exploratory Genetic Studies in Starting Treatment with Agonist Replacement Therapies (START)

Investigators:  Wade Berrettini, M.D., Ph.D., C. Lindsay DeVane, PharmD. Status:  Available at NIDA and dbGaP Abstract:  This proposal outlines a supplementary pharmacogenetics component to the NIDA START trial.  Patients participating in START will be offered the opportunity to volunteer for a genetics study that has the primary objective of genotyping patients for exploratory analyses.  Genomic DNA from blood samples sent...

Read more ...

Study 31 – Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT); CTN-0051

Ancillary Study: Contribution of Specified Opioid Receptor Gene Variants to Outcome of Extended Release Naltrexone vs. Buprenorphine/Naloxone Treatment for Opioid Dependence Investigators:  John Rotrosen, M.D. (NYU Langone Medical Center); Ancillary Study: Mary Jeanne Kreek, M.D. (Rockefeller University) Status:  Available at dbGaP Abstract:  For opioid-dependent patients in the U.S. and most of the rest of the world, detoxification or detoxification followed...

Read more ...

Study 39 – Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone: Improving the Real-World Effectiveness of Injection Naltrexone for Opioid Use Disorder (SWIFT)

CTN-0097: Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone: Improving the Real-World Effectiveness of Injection Naltrexone for Opioid Use Disorder (SWIFT) Investigator:  Adam Bisaga, M.D. Release Date:  TBA Objective: The primary goal of this hybrid effectiveness-implementation study is to determine whether the Rapid method of initiating treatment with extended-release injection naltrexone (XR-NTX) is non-inferior to a standard method on the...

Read more ...

Study 40 – Exemplar Hospital Initiation Trial to Enhance Treatment Engagement (EXHIT ENTREY)

CTN-0098: Exemplar Hospital Initiation Trial to Enhance Treatment Engagement (EXHIT ENTREY) Investigator:  Gavin Bart, M.D., Ph.D. Release Date:  TBA Objective: The primary objective of this study is to define and refine best practices for hospital-initiated treatment of opioid use disorder (OUD) and post-discharge treatment engagement by NIDA/CTNs expertise in hospital-based addiction care. Engagement in OUD care on the 34th day...

Read more ...

Study 41 – Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy

CTN-0100: Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy Investigators:  Edward Nunes, M.D., John Rotrosen, M.D., & Roger Weiss, M.D. Release Date:  TBA Objective: Although medications for opioid use disorder (MOUD) are highly effective, most studies show > 50% dropout at 3–6 months, and dropout carries a high risk of relapse. Among those who adhere to MOUD...

Read more ...